{"entity":{"id":"nct04655092","kind":"trial","name":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients","aka":[],"tldr":"A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia Japan K.K., now recruiting.","summary":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients is a phase 3 interventional study registered as NCT04655092 by PharmaEssentia Japan K.K., with 67 participants planned, started 2021-01-19 and due to reach its primary completion in 2026-06-30. Interventions recorded: P1101 (Ropeginterferon alfa-2b).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04655092","url":"https://clinicaltrials.gov/study/NCT04655092"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms","essential-thrombocythaemia","polycythaemia-vera"],"sections":[],"technologies":["cytokine-therapy"],"targets":[],"drugs":["ropeginterferon-alfa-2b"],"companies":["pharmaessentia"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04655092","phase":"3","setting":"Extension Study of P1101 in Japanese Patients Who Have Completed Phase 2 Single Arm Study in Polycythemia Vera (PV) Patients (Study A19-201) or Phase 3 Study in Essential Thrombocythemia (ET) Patients (Study P1101 ET)","sponsor":"PharmaEssentia Japan K.K.","started":"2021-01-19","startedType":"actual","enrolled":67,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04655092/","neighbours":{"cancer":[{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"}],"drug":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/"}],"company":[{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/"}]}}